The University of Chicago Header Logo

Ardaman Shergill

Concepts (122)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Circulating Tumor DNA
5
2024
48
2.960
Why?
Appendiceal Neoplasms
9
2024
31
2.560
Why?
Colorectal Neoplasms
11
2024
981
2.190
Why?
Peritoneal Neoplasms
11
2024
184
2.130
Why?
Hyperthermia, Induced
8
2024
73
1.620
Why?
Colonic Neoplasms
5
2024
573
1.260
Why?
Rectal Neoplasms
4
2024
127
0.830
Why?
Neoplasm Recurrence, Local
5
2024
1365
0.830
Why?
Precision Medicine
1
2024
410
0.680
Why?
Antineoplastic Combined Chemotherapy Protocols
14
2024
2566
0.670
Why?
Biomarkers, Tumor
3
2024
1549
0.660
Why?
Cytoreduction Surgical Procedures
11
2024
76
0.560
Why?
Adenocarcinoma
6
2024
1194
0.560
Why?
Fluorouracil
3
2024
561
0.460
Why?
Neoplasm Staging
4
2024
2018
0.380
Why?
Radiosurgery
2
2024
288
0.360
Why?
Liver Neoplasms
3
2024
758
0.330
Why?
Humans
31
2024
89357
0.310
Why?
Mutation
6
2024
4143
0.300
Why?
Celecoxib
2
2024
31
0.290
Why?
Combined Modality Therapy
7
2024
1719
0.280
Why?
Retrospective Studies
11
2024
9057
0.280
Why?
Neoadjuvant Therapy
3
2024
377
0.280
Why?
Survival Rate
7
2023
1901
0.270
Why?
Male
14
2024
42411
0.260
Why?
Female
14
2024
46202
0.250
Why?
Middle Aged
11
2024
25974
0.240
Why?
Aged, 80 and over
3
2024
6811
0.240
Why?
Cyclooxygenase 2 Inhibitors
1
2024
33
0.240
Why?
Class I Phosphatidylinositol 3-Kinases
1
2024
64
0.230
Why?
Adult
10
2024
26607
0.230
Why?
Quinolines
1
2024
91
0.230
Why?
Phenylurea Compounds
1
2024
115
0.230
Why?
Peritoneum
4
2024
57
0.220
Why?
Surgical Oncology
1
2023
27
0.220
Why?
Aged
7
2024
19165
0.220
Why?
Appendix
1
2023
31
0.210
Why?
Vaccines
1
2024
83
0.210
Why?
Cancer Vaccines
1
2024
160
0.210
Why?
Quality Assurance, Health Care
1
2024
225
0.210
Why?
C-Reactive Protein
1
2023
192
0.200
Why?
Molecular Targeted Therapy
1
2024
286
0.200
Why?
Ataxia Telangiectasia Mutated Proteins
1
2021
55
0.190
Why?
Palliative Care
1
2023
264
0.190
Why?
DNA Breaks, Double-Stranded
1
2021
66
0.190
Why?
Disease-Free Survival
4
2024
1214
0.190
Why?
Tumor Microenvironment
1
2024
463
0.180
Why?
Lung Neoplasms
2
2023
2362
0.180
Why?
Mitoxantrone
1
2020
68
0.180
Why?
Etoposide
1
2020
206
0.170
Why?
Cytarabine
1
2020
219
0.170
Why?
Leucovorin
3
2024
224
0.170
Why?
Antibodies, Monoclonal, Humanized
1
2024
969
0.160
Why?
Pancreatic Neoplasms
1
2024
669
0.150
Why?
Neoplasms
2
2024
3041
0.140
Why?
Protein Kinase Inhibitors
1
2021
605
0.140
Why?
Head and Neck Neoplasms
1
2021
1063
0.120
Why?
Carcinoma, Non-Small-Cell Lung
1
2023
1120
0.120
Why?
Myeloproliferative Disorders
1
2016
133
0.110
Why?
Leukemia, Myeloid, Acute
1
2020
793
0.110
Why?
Chemotherapy, Cancer, Regional Perfusion
2
2023
18
0.110
Why?
Carcinoembryonic Antigen
2
2023
40
0.100
Why?
Chemotherapy, Adjuvant
2
2024
487
0.100
Why?
Prospective Studies
3
2024
4289
0.090
Why?
Antineoplastic Agents
1
2021
2415
0.090
Why?
Recurrence
2
2023
1144
0.080
Why?
Cohort Studies
2
2023
2872
0.070
Why?
Quality of Life
2
2024
1668
0.060
Why?
Organoplatinum Compounds
1
2024
97
0.060
Why?
Capecitabine
1
2024
98
0.060
Why?
Standard of Care
1
2024
65
0.060
Why?
Trifluridine
1
2023
6
0.060
Why?
Advance Directives
1
2023
64
0.060
Why?
Microsatellite Instability
1
2023
49
0.050
Why?
Organ Sparing Treatments
1
2023
46
0.050
Why?
Preoperative Period
1
2023
94
0.050
Why?
Proto-Oncogene Proteins p21(ras)
1
2024
164
0.050
Why?
Neoplasm Grading
1
2024
374
0.050
Why?
Radiotherapy Planning, Computer-Assisted
1
2024
179
0.050
Why?
Carcinoma, Pancreatic Ductal
1
2024
112
0.050
Why?
HLA Antigens
1
2024
227
0.050
Why?
Anal Canal
1
2023
88
0.050
Why?
Monoterpenes
1
2022
5
0.050
Why?
Pyridines
1
2024
315
0.050
Why?
GPI-Linked Proteins
1
2022
51
0.050
Why?
Tumor Suppressor p53-Binding Protein 1
1
2021
12
0.050
Why?
Antigens, Neoplasm
1
2024
332
0.050
Why?
G2 Phase Cell Cycle Checkpoints
1
2021
12
0.050
Why?
Phosphatidylinositol 3-Kinases
1
2023
267
0.050
Why?
Interleukin-6
1
2023
261
0.050
Why?
Drug Combinations
1
2022
203
0.050
Why?
Vascular Endothelial Growth Factor A
1
2023
424
0.050
Why?
Preoperative Care
1
2023
396
0.050
Why?
Chemoradiotherapy
1
2023
309
0.050
Why?
Treatment Outcome
2
2024
8241
0.040
Why?
Tumor Burden
1
2021
308
0.040
Why?
Postoperative Period
1
2021
302
0.040
Why?
Administration, Oral
1
2022
682
0.040
Why?
Xenograft Model Antitumor Assays
1
2021
470
0.040
Why?
Tumor Suppressor Protein p53
1
2023
414
0.040
Why?
Mice, Nude
1
2021
815
0.040
Why?
Prevalence
1
2023
1243
0.040
Why?
Chronic Disease
1
2023
950
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2023
481
0.040
Why?
Double-Blind Method
1
2023
1719
0.040
Why?
Biopsy
1
2023
1184
0.040
Why?
Cell Cycle Proteins
1
2021
401
0.040
Why?
Disease Progression
1
2023
1489
0.040
Why?
Length of Stay
1
2021
736
0.040
Why?
Inflammation
1
2023
972
0.040
Why?
Biomarkers
1
2023
1767
0.030
Why?
Cell Line, Tumor
1
2021
2558
0.030
Why?
Cell Proliferation
1
2021
1652
0.030
Why?
Apoptosis
1
2021
1717
0.030
Why?
Prognosis
1
2023
3783
0.030
Why?
Illinois
1
2016
480
0.030
Why?
Kaplan-Meier Estimate
1
2016
860
0.030
Why?
Signal Transduction
1
2021
3385
0.020
Why?
Postoperative Complications
1
2021
2284
0.020
Why?
Young Adult
1
2020
6312
0.020
Why?
Mice
1
2021
11761
0.020
Why?
Animals
1
2021
27371
0.010
Why?
Shergill's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (122)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_